Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review

  title={Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review},
  author={Jean Bousquet and Ignacio J. Ansotegui and Giorgio Walter Canonica and Torsten Zuberbier and Carlos E. Baena-Cagnani and Claus Bachert and {\'A}lvaro Augusto Cruz and Sandra Nora Gonz{\'a}lez and Piotr Kuna and M{\'a}rio Morais‐Almeida and Joaquim Mullol and Dermot Ryan and Mario Sanchez‐Borges and Rom{\'a}n Valiente and Martin K. Church},
  journal={Current Medical Research and Opinion},
  pages={131 - 139}
Abstract Background: The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines development group examined the properties of oral H1-antihistamines and made proposals about an ‘optimal’ drug. Several criteria should be met by oral H1-antihistamines in terms of their pharmacological, and clinical efficacy and safety profiles. Objective: Bilastine, a new H1-antihistamine, has been approved in 28 European countries for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria… 

Bilastine: a lifetime companion for the treatment of allergies

Bilastine is a suitable option for the treatment of patients with allergic rhinoconjunctivitis or urticaria across age groups from school-age children to elderly patients, and has been shown to improve health-related quality of life.

Role of bilastine in the management of allergic rhinitis and urticaria: an Asia-Pacific consensus statement

The burgeoning prevalence of allergic diseases in the Asia-Pacific region and the uncontrolled symptoms that these patients experience demand a new antihistamine that offers the highest number of positive features according to the international guidelines.

Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria

During clinical development, bilastine was shown to be a drug that is adequately tolerated, with a similar effect to placebo with regard to drowsiness and changes in heart rate, and headaches were the most frequent adverse effect to be reported.

Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions based on queries received by the medical information department

Bilastine was evaluated in many patients throughout the clinical development required for its approval, but clinical trials generally exclude many patients who will benefit in everyday clinical practice (especially those with coexisting diseases and/or being treated with concomitant drugs).

Allergic rhinitis: current options and future perspectives

Available and new drugs under investigation seem able to control rhinitis symptoms without a significant patient's burden, and the challenge for the next years will be to improve treatment adherence rather than to introduce new drugs.

Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis

Bilastine is effective and safe in treating the overall symptoms of AR with comparable efficacy and safety with other OAHs except somnolence, which is notably less in bilastine.

Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine

Bilastine is generally well tolerated, both at standard and at supratherapeutic doses, appears to have less sedative potential than other second-generation antihistamines, and has no cardiotoxicity.

Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and Urticaria

The observations indicate that non-sedating antihistamines, as opposed to what has been thought previously, may be helpful in patients with allergic rhinitis in whom nasal obstruction is a major concern.

Features of the modern antihistamines use in the treatment of allergic rhinitis

The research results proved the high antihistaminic activity of bilastine 20 mg in vitro and in vivo, the absence of cardiac and sedative side effects on the central nervous system, the ability to eliminate the nasal and ocular symptoms of disease and improve the quality of life of patients with allergic rhinitis.

Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions

An update of a previous review, with a focus on recent clinical information on the use of bilastine in paediatric and other populations, provides current data regarding the best use of the drug in specific situations and patients and identifies areas in which further knowledge is required.



Bilastine for the relief of allergy symptoms.

Oral treatment with bilastine 20 mg once daily improved allergic rhinitis with greater efficacy than placebo and comparable to cetirizine and desloratadine, and relieving symptoms, improving quality of life and controlling sleep disorders.

Requirements for medications commonly used in the treatment of allergic rhinitis

There is an urgent need to make internationally valid definitions of the properties of oral H1-antihistamines, anti-allergic effects of H 1-antishistamines and intra-nasal corticosteroids, for physicians and scientists but also for drug companies developing new drugs and registration authorities.

Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA2LEN Study

This study showed desloratadine (DL) to be effective and safe in the treatment of persistent allergic rhinitis and improved quality of life.

Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria

  • M. Church
  • Medicine
    Expert opinion on drug safety
  • 2011
Bilastine has high selectivity for H1-receptors, is rapidly and effectively absorbed, undergoes negligible metabolism and is a substrate for P-glycoprotein, which limits its passage across the blood–brain barrier.

Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis

A post-hoc analysis indicated that bilastine and cetirizine were similarly effective and more effective than placebo during a 4-week treatment period in patients with PAR and was shown to be safe and well-tolerated over a 1-year treatment period.

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.

Development and implementation of guidelines in allergic rhinitis – an ARIA-GA 2 LEN paper

The goal of the ARIA guidelines is to provide recommendations about the best management options for most patients in most situations, and these recommendations should be based on the best available evidence.

Guidelines for allergic rhinitis need to be used in primary care.

Clinical Practice Guidelines for allergicRhinitis have been developed over the past 15 years and have been found to improve the care for patients with allergic rhinitis and were based on various evidencebased models.

The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber

Bilastine, like cetirizine and fexofenadine, was safe and well tolerated in this study and had a rapid onset of action within 1 h, and a long duration of action, greater than 26 h.

Pharmacologic and anti‐IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN)

This document updates the ARIA sections on the pharmacologic and anti‐IgE treatments of allergic rhinitis and only a few studies assessing nasal and non‐nasal symptoms are presented.